Altimmune Inc (ALT)
NASDAQ:ALT
Total Valuation
Altimmune has a market cap or net worth of $416.22M. The enterprise value is $274.35M.
Market Cap$416.22M
Enterprise Value$274.35M
Share Statistics
Altimmune has 130,069,980 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding130,069,980
Owned by Insiders0.65%
Owned by Institutions5.75%
Financial Efficiency
Altimmune’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -35.36%.
Return on Equity (ROE)-0.39
Return on Assets (ROA)-0.31
Return on Invested Capital (ROIC)-35.36%
Return on Capital Employed (ROCE)-0.36
Revenue Per Employee694.92
Profits Per Employee-1.49M
Employee Count59
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Altimmune is ―. Altimmune’s PEG ratio is 0.14.
PE Ratio―
PS Ratio7757.46
PB Ratio1.41
Price to Fair Value1.41
Price to FCF-4.71
Price to Operating Cash Flow-4.75
PEG Ratio0.14
Income Statement
In the last 12 months, Altimmune had revenue of 41.00K and earned -88.09M in profits. Earnings per share was -1.00.
Revenue41.00K
Gross Profit-71.00K
Operating Income-94.49M
Pretax Income-88.77M
Net Income-88.09M
EBITDA-94.49M
Earnings Per Share (EPS)-1.00
Cash Flow
In the last 12 months, operating cash flow was -67.83M and capital expenditures -11.00K, giving a free cash flow of -67.84M billion.
Operating Cash Flow-67.83M
Free Cash Flow-67.84M
Free Cash Flow per Share-0.52
Dividends & Yields
Altimmune pays an annual dividend of $873, resulting in a dividend yield of ―
Dividend Per Share$873
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.67
52-Week Price Change-39.85%
50-Day Moving Average4.36
200-Day Moving Average4.32
Relative Strength Index (RSI)32.03
Average Volume (3m)3.49M
Important Dates
Altimmune upcoming earnings date is May 19, 2026, TBA (Confirmed).
Last Earnings DateMar 5, 2026
Next Earnings DateMay 19, 2026
Ex-Dividend Date―
Financial Position
Altimmune as a current ratio of 18.55, with Debt / Equity ratio of 15.87%
Current Ratio18.55
Quick Ratio18.55
Debt to Market Cap0.11
Net Debt to EBITDA0.09
Interest Coverage Ratio-57.76
Taxes
In the past 12 months, Altimmune has paid -681.00K in taxes.
Income Tax-681.00K
Effective Tax Rate<0.01
Enterprise Valuation
Altimmune EV to EBITDA ratio is -3.28, with an EV/FCF ratio of -4.59.
EV to Sales7.56K
EV to EBITDA-3.28
EV to Free Cash Flow-4.59
EV to Operating Cash Flow-4.59
Balance Sheet
Altimmune has $273.46M in cash and marketable securities with $35.69M in debt, giving a net cash position of $237.77M billion.
Cash & Marketable Securities$273.46M
Total Debt$35.69M
Net Cash$237.77M
Net Cash Per Share$1.83
Tangible Book Value Per Share$2.55
Margins
Gross margin is -36387.80%, with operating margin of -230460.98%, and net profit margin of -214860.98%.
Gross Margin-36387.80%
Operating Margin-230460.98%
Pretax Margin-216521.95%
Net Profit Margin-214860.98%
EBITDA Margin-230460.98%
EBIT Margin-230460.98%
Analyst Forecast
The average price target for Altimmune is $13.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$13.50
Price Target Upside321.88% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast-61.54%
EPS Growth Forecast31.25%